Data / New clinical trials / Carcinoma, Renal Cell

Carcinoma, Renal Cell trials: 226 new since Nov 2024

Name: New Carcinoma, Renal Cell clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Carcinoma, Renal Cell clinical trials: 226 rows for $11.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 9 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/carcinoma-renal-cell, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

226 clinical studies in Carcinoma, Renal Cell were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 57 have an industry sponsor and 178 are recruiting or about to. The newest, NCT07925333, was posted on November 9, 2026: Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer (Beth Israel Deaconess Medical Center).

The request: Every new Carcinoma, Renal Cell clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

226New trials
57Industry sponsored
178Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 226, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07925333	Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer	Beth Israel Deaconess Medical Center	Phase 2	Not yet recruiting	Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)	10	United States	clinicaltrials.gov
November 6, 2026	NCT07922915	Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma	Sun Yat-sen University	Phase 2	Not yet recruiting	Localized Clear Cell Renal Cell Carcinoma	24		clinicaltrials.gov
November 2, 2026	NCT07911527	The Edison™ System for Treatment of Renal Tumors Using Histotripsy (Histo-Renal Trial)	Chinese University of Hong Kong	Not applicable	Not yet recruiting	Renal Tumors	15		clinicaltrials.gov
November 2, 2026	NCT07909265	Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	Recruiting	Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma	54	China	clinicaltrials.gov
October 28, 2026	NCT07901569	Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma	Liu Zhuo	Observational	Not yet recruiting	Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus	273	China	clinicaltrials.gov
October 16, 2026	NCT07877194	A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer	Summit Therapeutics	Phase 2	Not yet recruiting	Renal Cell Carcinoma, Clear Cell	100	China, United States	clinicaltrials.gov
October 15, 2026	NCT07875959	18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors	Peking University First Hospital	Not applicable	Recruiting	Renal Cell Carcinoma (RCC), Renal Pelvic Urothelial Carcinoma	80	China	clinicaltrials.gov
October 15, 2026	NCT07875946	68Ga- and 18F-CAIX PET Imaging Study	Peking University First Hospital	Early phase 1	Not yet recruiting	Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor	100	China	clinicaltrials.gov
October 15, 2026	NCT07874542	Plasma DNA Methylation for Preoperative Classification of Renal Masses	RenJi Hospital	Observational	Recruiting	Renal Cell Carcinoma, Benign Renal Mass	240	China	clinicaltrials.gov
October 13, 2026	NCT07872553	A Study of Treatment Delivery Preference In People With Kidney Cancer	Memorial Sloan Kettering Cancer Center	Phase 4	Recruiting	Renal Cell Carcinoma, Kidney Cancer	40	United States	clinicaltrials.gov
October 13, 2026	NCT07870746	Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC	Telix Pharmaceuticals (Innovations) Pty Limited	Phase 2	Not yet recruiting	ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell...	40	United States	clinicaltrials.gov
October 8, 2026	NCT07865832	A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma	Liangyou Gu	Early phase 1	Not yet recruiting	Clear Cell Renal Cell Carcinoma	6	China	clinicaltrials.gov
October 7, 2026	NCT07863024	Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET...	Regeneron Pharmaceuticals	Phase 1/2	Not yet recruiting	Advanced Solid Tumors	320		clinicaltrials.gov
October 1, 2026	NCT07853001	Patient Reported Outcomes and Different Renal Artery Clamping Techniques During Robot Assisted Kidney Resection	Bjarte Almas	Not applicable	Not yet recruiting	Renal Cell Carcinoma (Kidney Cancer)	130	Norway	clinicaltrials.gov
October 1, 2026	NCT07852884	First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain	Bristol-Myers Squibb	Observational	Active not recruiting	Renal Cell Carcinoma (RCC)	1,200	Spain	clinicaltrials.gov
September 30, 2026	NCT07848295	A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	Not yet recruiting	Clear Cell Renal Cell Carcinoma (ccRCC)	112	Belgium, France, Germany, Italy, Netherlands, Spain, United States	clinicaltrials.gov
September 25, 2026	NCT07841756	Federated Learning in Renal Tumor Model	First Affiliated Hospital of Guangxi Medical University	Observational	Not yet recruiting	Renal Tumors	3,000	China	clinicaltrials.gov
September 24, 2026	NCT07840001	Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma	Peter MacCallum Cancer Centre, Australia	Phase 2	Not yet recruiting	Locally Advanced Clear Cell Renal Cell Carcinoma	30	Australia	clinicaltrials.gov
September 22, 2026	NCT07833085	CAIX-targeted PET/CT in Solid Tumors	Zhongnan Hospital	Not applicable	Recruiting	Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer	100	China	clinicaltrials.gov
September 18, 2026	NCT07828704	Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA	Henry Ford Health System	Phase 2	Recruiting	Kidney Cancers	10	United States	clinicaltrials.gov
September 18, 2026	NCT07827482	Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell...	First Affiliated Hospital of Fujian Medical University	Observational	Completed	Metastatic Renal Cell Carcinoma	228	China	clinicaltrials.gov
September 14, 2026	NCT07816770	MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas	Fudan University	Phase 2	Not yet recruiting	Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas	30		clinicaltrials.gov
September 4, 2026	NCT07805122	Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma	Centro di Riferimento Oncologico - Aviano	Not applicable	Recruiting	Renal Cell Carcinoma	216	Italy	clinicaltrials.gov
September 3, 2026	NCT07803315	Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy	University of Leipzig	Observational	Recruiting	Kidney Neoplasm, Renal Mass up to 7cm	60	Germany	clinicaltrials.gov
August 20, 2026	NCT07776717	TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal...	Fudan University	Phase 2	Not yet recruiting	Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma	30		clinicaltrials.gov
August 18, 2026	NCT07770802	Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)	Hangzhou Huasai Biomedicine Co., Ltd.	Phase 1	Recruiting	Clear Cell Renal Cell Carcinoma	15	China	clinicaltrials.gov
August 17, 2026	NCT07768306	Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in...	Norroy Bioscience Co., LTD	Phase 1	Not yet recruiting	Clear Cell Renal Cell Carcinoma (ccRCC)	20		clinicaltrials.gov
August 7, 2026	NCT07753343	Identification and Description of Patients With High-risk Non Metastatic RCC	University Hospital, Bordeaux	Observational	Recruiting	Renal Cell Carcinoma	6,109	France	clinicaltrials.gov
August 6, 2026	NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	Arvinas Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor	499	United States	clinicaltrials.gov
August 6, 2026	NCT07748988	Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma	Vanderbilt-Ingram Cancer Center	Phase 1	Recruiting	Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma	12	United States	clinicaltrials.gov
August 4, 2026	NCT07743749	An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Recruiting	Renal Tumor, Kidney Neoplasm	900	China	clinicaltrials.gov
July 21, 2026	NCT07716735	Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney...	Jonsson Comprehensive Cancer Center	Phase 1	Not yet recruiting	Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma...	18	United States	clinicaltrials.gov
July 20, 2026	NCT07715565	Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell...	West China Hospital	Phase 2	Not yet recruiting	Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy	66	China	clinicaltrials.gov
July 20, 2026	NCT07714018	Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active...	Roswell Park Cancer Institute	Not applicable	Recruiting	Renal Cell Carcinoma (RCC)	20	United States	clinicaltrials.gov
July 15, 2026	NCT07704970	QLESP Block for Pain Control in Robotic Partial Nephrectomy	Huazhong University of Science and Technology	Not applicable	Recruiting	Renal Cell Carcinoma (Kidney Cancer), Postoperative Pain, Nerve Block	120	China	clinicaltrials.gov
July 13, 2026	NCT07697417	Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma	Tianjin Medical University Second Hospital	Observational	Active not recruiting	Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function, Partial Nephrectomy...	406	China	clinicaltrials.gov
July 8, 2026	NCT07689812	A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI)...	Natera, Inc.	Not applicable	Not yet recruiting	NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma)...	920		clinicaltrials.gov
July 8, 2026	NCT07689240	Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma	National Cancer Institute (NCI)	Phase 3	Not yet recruiting	Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	400		clinicaltrials.gov
July 7, 2026	NCT07688187	A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma	PeptiDream Inc.	Phase 1	Recruiting	Clear Cell Renal Cell Carcinoma	60	United States	clinicaltrials.gov
July 7, 2026	NCT07686744	Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma	Jian Lin	Phase 1	Not yet recruiting	Renal Cell Carcinoma, Advanced, Recurrent, Refractory	8	China	clinicaltrials.gov
July 2, 2026	NCT07680556	Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma	Radboud University Medical Center	Not applicable	Recruiting	Oncology	30	Netherlands	clinicaltrials.gov
June 18, 2026	NCT07657325	Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma	Tianjin Medical University Second Hospital	Observational	Recruiting	Renal Cell Carcinoma (RCC)	110	China	clinicaltrials.gov
June 15, 2026	NCT07647744	To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer	Hrain Biotechnology Co., Ltd.	Phase 1	Recruiting	Renal Cell Carcinoma (RCC)	18	China	clinicaltrials.gov
June 12, 2026	NCT07645742	Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors	West Virginia University	Not applicable	Not yet recruiting	Cancer (Advanced Stage)	90		clinicaltrials.gov
June 9, 2026	NCT07636785	A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors	VM Discovery, Inc.	Phase 1/2	Recruiting	Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer...	111	United States	clinicaltrials.gov
June 9, 2026	NCT07636148	Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance	Mark C Burgmans, MD PhD	Observational	Recruiting	Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor, Kidney...	2,000	France, Netherlands	clinicaltrials.gov
June 4, 2026	NCT07627464	Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	Renal Cell Carcinoma (RCC)	144	China	clinicaltrials.gov
June 3, 2026	NCT07623369	A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors	Huahui Health	Phase 1	Recruiting	Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell...	299	Australia, China	clinicaltrials.gov
June 2, 2026	NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	Exelixis	Phase 3	Enrolling by invitation	Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)...	5,000	United States	clinicaltrials.gov
May 22, 2026	NCT07602101	Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma	RenJi Hospital	Phase 2	Not yet recruiting	Clear Cell Renal Cell Carcinoma	33		clinicaltrials.gov
May 18, 2026	NCT07594106	REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic...	Regeneron Pharmaceuticals	Phase 1/2	Recruiting	Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)	265	United States	clinicaltrials.gov
May 18, 2026	NCT07593040	Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma	Vall d'Hebron Institute of Oncology	Phase 2	Not yet recruiting	Renal Cell Carcinoma	150	Spain	clinicaltrials.gov
May 11, 2026	NCT07578025	Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy	City of Hope Medical Center	Phase 2	Not yet recruiting	Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8	34	United States	clinicaltrials.gov
May 8, 2026	NCT07576725	Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial	Fred Hutchinson Cancer Center	Phase 2	Not yet recruiting	Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical...	50	Uganda	clinicaltrials.gov
May 6, 2026	NCT07571551	Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma	Jinling Hospital, China	Phase 2	Recruiting	Clear Cell RCC	75	China	clinicaltrials.gov
May 4, 2026	NCT07564232	Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma	M.D. Anderson Cancer Center	Phase 1	Recruiting	Clear Cell Renal Cell Carcinoma	40	United States	clinicaltrials.gov
April 29, 2026	NCT07557225	18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors	Peking University First Hospital	Not applicable	Recruiting	Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer...	200	China	clinicaltrials.gov
April 29, 2026	NCT07555210	Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy	Jessica Mezzanotte Sharpe	Not applicable	Recruiting	Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer)...	25	United States	clinicaltrials.gov
April 24, 2026	NCT07551349	Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma	Beijing Biotech	Phase 1/2	Recruiting	Advanced or Metastatic Clear Cell Renal Cell Carcinoma	36	China	clinicaltrials.gov
April 20, 2026	NCT07540260	CAIX PET/ CT Guided Radiation Therapy in CcRCC.	Peking University First Hospital	Not applicable	Recruiting	Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer	70	China	clinicaltrials.gov
April 8, 2026	NCT07517198	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	Phase 1	Recruiting	Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin...	40	United States	clinicaltrials.gov
April 8, 2026	NCT07516366	Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell...	National Cancer Institute (NCI)	Phase 2	Recruiting	Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV...	16	United States	clinicaltrials.gov
April 3, 2026	NCT07510334	VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma	Mayo Clinic	Phase 2	Recruiting	Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC...	18	United States	clinicaltrials.gov
March 30, 2026	NCT07500831	Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma	Qilu Hospital of Shandong University	Not applicable	Not yet recruiting	Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma	43	China	clinicaltrials.gov
March 30, 2026	NCT07500805	UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma	UTC Therapeutics Inc.	Phase 1	Not yet recruiting	CD70-positive Advanced Renal Clear Cell Carcinoma	21	China	clinicaltrials.gov
March 27, 2026	NCT07497958	Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy	Sun Yat-sen University	Not applicable	Not yet recruiting	Renal Cell Carcinoma (RCC), Renal Function Abnormal	174	China	clinicaltrials.gov
March 27, 2026	NCT07494435	Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC	Zhejiang Haichang Biotech Co., Ltd.	Phase 2	Not yet recruiting	Hepato Cellular Carcinoma (HCC), Renal Cell Cancer	230	China	clinicaltrials.gov
March 24, 2026	NCT07489495	A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)	Merck Sharp & Dohme LLC	Phase 3	Recruiting	Carcinoma, Renal Cell	758	Argentina, Australia, Brazil, Canada, Chile, Czechia, Denmark, France, Germany...	clinicaltrials.gov
March 23, 2026	NCT07488572	Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI...	Sun Yat-sen University	Phase 2	Enrolling by invitation	Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma	60	China	clinicaltrials.gov
March 20, 2026	NCT07485114	Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung...	Daniel Keizman	Observational	Recruiting	Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Transitional Cell Carcinoma	300	Israel	clinicaltrials.gov
March 18, 2026	NCT07480044	A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After...	Zhejiang University	Not applicable	Not yet recruiting	Postoperative Delirium (POD), Prostate Cancer, Kidney Tumor	220	China	clinicaltrials.gov
March 13, 2026	NCT07470840	SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma	Fujian Cancer Hospital	Phase 2	Not yet recruiting	Locally Advanced or Metastatic Renal Cell Carcinoma	27	China	clinicaltrials.gov
March 13, 2026	NCT07469683	An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib...	Yonsei University	Phase 2	Recruiting	Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis	78	South Korea	clinicaltrials.gov
March 12, 2026	NCT07465458	Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients	Humanitas Hospital, Italy	Observational	Not yet recruiting	Renal Carcinoma	226	Italy, Spain	clinicaltrials.gov
March 10, 2026	NCT07461090	Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis	Menoufia University	Not applicable	Recruiting	Nonfunctioning Kidney, Renal Cell Carcinoma (RCC)	60	Egypt	clinicaltrials.gov
March 10, 2026	NCT07460206	Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment	Gruppo Oncologico Italiano di Ricerca Clinica	Phase 2	Not yet recruiting	ccRCC	108		clinicaltrials.gov
February 27, 2026	NCT07436416	Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer	Institute of Oncology Ljubljana	Not applicable	Completed	Renal Cell Carcinoma	91	Slovenia	clinicaltrials.gov
February 19, 2026	NCT07419841	A Phase 1 Study of the Safety and Tolerability of CTX-10726	Compass Therapeutics	Phase 1	Recruiting	Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)	70	United States	clinicaltrials.gov
February 12, 2026	NCT07406646	Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)	Institute of Oncology Ljubljana	Not applicable	Completed	Renal Cell Carcinoma, Advanced Kidney Cancer	91	Slovenia	clinicaltrials.gov
February 12, 2026	NCT07405086	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study	OHSU Knight Cancer Institute	Phase 4	Recruiting	Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma...	160	United States	clinicaltrials.gov
February 11, 2026	NCT07402109	CBCT Guided Markerless SBRT for Renal Cell Cancer	Erasmus Medical Center	Not applicable	Recruiting	Renal Cell Carcinoma (RCC)	40	Netherlands	clinicaltrials.gov
February 9, 2026	NCT07397611	Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC	Dana-Farber Cancer Institute	Phase 2	Recruiting	Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma	32	United States	clinicaltrials.gov
February 5, 2026	NCT07389629	Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC	Sun Yat-sen University	Phase 2	Recruiting	Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy	25	China	clinicaltrials.gov
February 4, 2026	NCT07386158	Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC	Sun Yat-sen University	Phase 2	Recruiting	Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy	21	China	clinicaltrials.gov
February 3, 2026	NCT07383441	Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer	SWOG Cancer Research Network	Phase 3	Recruiting	Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC...	718	United States	clinicaltrials.gov
January 27, 2026	NCT07369505	Sapu003 in Advanced mTOR-sensitive Solid Tumors	SAPU NANO (US) LLC	Phase 1	Recruiting	Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)...	27	Australia	clinicaltrials.gov
January 20, 2026	NCT07351266	Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Not yet recruiting	Renal Cell Carcinoma (Kidney Cancer)	10		clinicaltrials.gov
January 16, 2026	NCT07346404	Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma	Assistance Publique - Hôpitaux de Paris	Phase 2	Not yet recruiting	Renal Cell Carcinoma	50	France	clinicaltrials.gov
January 12, 2026	NCT07332923	Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning	First Affiliated Hospital of Fujian Medical University	Observational	Active not recruiting	Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram	500	China	clinicaltrials.gov
January 8, 2026	NCT07326280	The Cold Ischemia Robot-assisted Partial Nephrectomy	Sun Yat-sen University	Not applicable	Recruiting	Renal Cell Carcinoma, Renal Function Abnormal	310	China	clinicaltrials.gov
January 6, 2026	NCT07321197	Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)	Tianjin Medical University Second Hospital	Not applicable	Recruiting	Renal Cell Carcinoma (Kidney Cancer)	220	China	clinicaltrials.gov
December 24, 2025	NCT07301827	Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Not applicable	Recruiting	Renal Cell Carcinoma	66	China	clinicaltrials.gov
December 23, 2025	NCT07300241	Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma	Neomorph, Inc	Phase 1	Recruiting	Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC...	30	United States	clinicaltrials.gov
December 22, 2025	NCT07297667	GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours	Canadian Cancer Trials Group	Phase 1	Recruiting	Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer	30	Canada	clinicaltrials.gov
December 19, 2025	NCT07294859	Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy	Jinling Hospital, China	Observational	Recruiting	Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury	285	China	clinicaltrials.gov
December 19, 2025	NCT07293351	A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With...	Bristol-Myers Squibb	Phase 1/2	Recruiting	Advanced Renal Cell Carcinoma (RCC)	474	Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Finland, France...	clinicaltrials.gov
December 16, 2025	NCT07285044	The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment...	Mayo Clinic	Phase 2	Recruiting	Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma...	27	United States	clinicaltrials.gov
December 16, 2025	NCT07284953	A Novel Haemostatic Agent for Robotic Partial Nephrectomy	The Royal Wolverhampton Hospitals NHS Trust	Not applicable	Withdrawn	Kidney Cancer, Renal Cell Carcinoma	0	United Kingdom	clinicaltrials.gov
December 11, 2025	NCT07277972	Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear...	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	RCC, Renal Cell Cancer	36		clinicaltrials.gov
December 1, 2025	NCT07256223	A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread	Fudan University	Phase 2	Not yet recruiting	Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis	30		clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Sun Yat-sen University	8	November 6, 2026
M.D. Anderson Cancer Center	7	May 4, 2026
Peking University First Hospital	5	October 15, 2026
First Affiliated Hospital of Fujian Medical University	5	September 18, 2026
Tianjin Medical University Second Hospital	5	July 13, 2026
City of Hope Medical Center	5	May 11, 2026
Jinling Hospital, China	5	May 6, 2026
RenJi Hospital	4	October 15, 2026
Bristol-Myers Squibb	4	October 1, 2026
Fudan University	4	September 14, 2026
Merck Sharp & Dohme LLC	4	March 24, 2026
AstraZeneca	4	August 15, 2025
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	3	November 2, 2026
Memorial Sloan Kettering Cancer Center	3	October 13, 2026
Telix Pharmaceuticals (Innovations) Pty Limited	3	October 13, 2026
Mayo Clinic	3	April 3, 2026
Shao Pengfei	3	June 13, 2025
Regeneron Pharmaceuticals	2	October 7, 2026
National Cancer Institute (NCI)	2	July 8, 2026
Tianjin Medical University Cancer Institute and Hospital	2	June 4, 2026

By phase

Phase	New trials	Latest
Phase 2	61	November 9, 2026
Observational	47	October 28, 2026
Not applicable	44	November 2, 2026
Phase 1	35	September 30, 2026
Phase 1/2	18	October 7, 2026
Phase 3	11	July 8, 2026
Phase 4	5	October 13, 2026
Early phase 1	4	October 15, 2026
Phase 2/3	1	July 25, 2025

By country

Country	New trials	Latest
United States	77	November 9, 2026
China	77	November 2, 2026
Italy	17	September 30, 2026
Australia	14	September 24, 2026
Spain	12	October 1, 2026
France	12	September 30, 2026
South Korea	9	March 24, 2026
Germany	8	September 30, 2026
United Kingdom	7	March 24, 2026
Netherlands	6	September 30, 2026
Canada	6	March 24, 2026
Denmark	5	March 24, 2026
Israel	5	March 24, 2026
Brazil	4	March 24, 2026
Chile	4	March 24, 2026
Czechia	4	March 24, 2026
Japan	4	December 19, 2025
Belgium	3	September 30, 2026
Argentina	3	March 24, 2026
Poland	3	March 24, 2026
Turkey (Türkiye)	3	March 24, 2026
Egypt	3	March 10, 2026
Greece	2	March 24, 2026
Slovenia	2	February 27, 2026
Ireland	2	December 19, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.